GSK submits melanoma drug combo for FDA approval

07/10/2013 | Reuters

GlaxoSmithKline filed an application with the FDA for approval to market a combination of dabrafenib and trametinib as a treatment for melanoma. The application is supported by data from a Phase I/II trial. Dabrafenib and trametinib, sold under the brand names Tafinlar and Mekinist, respectively, were individually approved by the FDA in May.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT